NA
PYXS icon

NewEdge Advisors’s Pyxis Oncology PYXS Stock Holding History

NewEdge Advisors’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.9K Hold
10,250
– – ﹤0.01% 3245
2026
Q1 		$15K Hold
10,250
– – ﹤0.01% 3288
2025
Q4 		$11.8K Buy
10,250
+10,000
+4,000% +$35.3K ﹤0.01% 3423
2025
Q3 		$555 Hold
250
– – ﹤0.01% 3942
2025
Q2 		$275 Hold
250
– – ﹤0.01% 3860
2025
Q1 		$245 Hold
250
– – ﹤0.01% 3784
2024
Q4 		$390 Hold
250
– – ﹤0.01% 3692
2024
Q3 		$918 Hold
250
– – ﹤0.01% 3527
2024
Q2 		$828 Hold
250
– – ﹤0.01% 3505
2024
Q1 		$1.06K Hold
250
– – ﹤0.01% 3483
2023
Q4 		$450 Sell
250
-1,542
-86% -$2.64K ﹤0.01% 3542
2023
Q3 		$3.57K Hold
1,792
– – ﹤0.01% 2901
2023
Q2 		$4.59K Buy
1,792
+1,542
+617% +$4.89K ﹤0.01% 2847
2023
Q1 		$1K Buy
+250
New +$499 ﹤0.01% 3150

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NewEdge Advisors's PYXS Position: Q2 2026 in Review

NewEdge Advisors held its Pyxis Oncology (PYXS) position steady in Q2 2026 at 10,250 shares worth $30.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3245.

NewEdge Advisors first reported a position in PYXS in Q1 2023 and has held it in 14 quarters since. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • NewEdge Advisors held 10,250 shares of Pyxis Oncology worth $30.9K as of Q2 2026.
  • NewEdge Advisors left its Pyxis Oncology share count unchanged in Q2 2026.
  • Pyxis Oncology made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3245 holding.
  • NewEdge Advisors first reported a position in Pyxis Oncology in Q1 2023 and has held it in 14 quarters since.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.